HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lazaroid U-83836E improves tolerance to hemorrhagic shock and limb ischemia and reperfusion in rats and increases cardiac heat shock protein 72.

AbstractOBJECTIVES:
Aminosteroids of the lazaroid type protect organs from ischemia-reperfusion damage. The authors hypothesized that lazaroid U-83836E may be beneficial in a shock model with hemorrhage combined with limb ischemia. Furthermore, the authors hypothesized that lazaroids induce expression of heat shock proteins (HSPs) of the 72-kDa family.
METHODS:
Rats were divided into two groups (lazaroid and control groups, n = 8 each) and pretreated with the lazaroid U-83836E (5 mg/kg) or with vehicle intraperitoneally at 12 and 24 hours before experiments. At the time of the experiment, rats were anesthetized, and the femoral artery of each rat was cannulated. After 20 minutes of stabilization, blood was shed from each rat to bring its mean arterial pressure to 24-28 mmHg for 2 hours. Bilateral tourniquets were tightened proximally on the rat thighs during those 2 hours and then released. Shed blood plus equal amounts of Ringer acetate then were infused to restore normal blood pressure, followed by a continuous infusion of Ringer acetate, the rate of which was regulated to maintain blood pressure, until 30 minutes after start of resuscitation. Fluid resuscitation was stopped, and rats were observed for another 3.5 hours. At the end of the observation period, the rats' hearts were collected for immunoblot analysis of HSP72. Additional hearts were collected from similarly pretreated rats not undergoing the episode of hemorrhagic shock and fluid resuscitation.
RESULTS:
Pretreatment with U-83836E improved mean arterial blood pressure after hemorrhagic shock and fluid resuscitation (p = 0.02), combined with improvements in acid-base balance (improved base excess and standard bicarbonate; p = 0.02 and p = 0.01, respectively). Western blot of cardiac protein extracts demonstrated that lazaroid pretreatment increased expression of HSP72.
CONCLUSIONS:
Pretreatment with the lazaroid U-83836E improved outcome markers in this hemorrhagic shock model. The observed protection may be caused by increased expression of HSP72.
AuthorsFausto Labruto, Xiaoliang Song, Guro Valen, Jarle Vaage
JournalAcademic emergency medicine : official journal of the Society for Academic Emergency Medicine (Acad Emerg Med) Vol. 13 Issue 1 Pg. 7-12 (Jan 2006) ISSN: 1553-2712 [Electronic] United States
PMID16365323 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antioxidants
  • Biomarkers
  • Chromans
  • HSP72 Heat-Shock Proteins
  • Piperazines
  • U 78517F
Topics
  • Acid-Base Equilibrium (drug effects)
  • Animals
  • Antioxidants (pharmacology)
  • Biomarkers (metabolism)
  • Blood Pressure (drug effects)
  • Body Temperature (drug effects)
  • Chromans (pharmacology)
  • Disease Models, Animal
  • HSP72 Heat-Shock Proteins (metabolism)
  • Ischemia (complications, drug therapy, metabolism)
  • Lower Extremity (blood supply)
  • Male
  • Piperazines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Reference Values
  • Reperfusion Injury (complications, drug therapy, metabolism)
  • Shock, Hemorrhagic (complications, drug therapy, metabolism)
  • Water-Electrolyte Balance (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: